Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?


Creative Commons License

YONTAR O. C. , YILMAZ M. B. , YALTA K., TANDOĞAN İ.

ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY, cilt.10, ss.310-316, 2010 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 10 Konu: 4
  • Basım Tarihi: 2010
  • Doi Numarası: 10.5152/akd.2010.088
  • Dergi Adı: ANADOLU KARDIYOLOJI DERGISI-THE ANATOLIAN JOURNAL OF CARDIOLOGY
  • Sayfa Sayıları: ss.310-316

Özet

Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosimendan does not increase cellular calcium intake, so that, does not cause intracellular calcium overload and related arrhythmias. Atrial fibrillation (AF) was shown to be an independent risk factor for mortality and morbidity in large heart failure (HF) trials. Heart failure induces AF, AF aggravates HF and therefore they generally coexist. We conducted a study to investigate if there is any differential effect of Levosimendan in HF patients with chronic AF and without AF.